Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma

Blood

Volumn 123, Issue 4, 2014, Pages 530-540

  Fish, Kamonwan ^a   Chen, Jia ^a   Longnecker, Richard ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPSTEIN BARR VIRUS LATENT MEMBRANE PROTEIN 2A; LATENT MEMBRANE PROTEIN 2; MUTANT PROTEIN; MYC PROTEIN; PRE B CELL RECEPTOR; S10A PROTEIN; UNCLASSIFIED DRUG; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; GAIN OF FUNCTION MUTATION; GENE REPRESSION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; VIRUS CARCINOGENESIS; ACTIVE TRANSPORT; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE MODEL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HOMOZYGOTE; HUMAN; LYMPHOMA; METABOLISM; MUTATION; PHENOTYPE; TRANSGENIC MOUSE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMOZYGOTE; HUMANS; LYMPHOMA; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MYC; VIRAL MATRIX PROTEINS;

EID: 84893046503     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-517649     Document Type: Article

References (61)

1. Blackwood EM, Eisenman RN. Max: a helix-loophelix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 1991; 251(4998):1211-1217. (Pubitemid 21926213)
2. Blackwood EM, Lüscher B, Eisenman RN. Myc and Max associate in vivo. Genes Dev. 1992;6(1): 71-80.
3. Lin CY, Lovén J, Rahl PB, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151(1):56-67.
4. Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151(1):68-79.
5. de Alboran IM, O'Hagan RC, Gärtner F, et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity. 2001;14(1):45-55. (Pubitemid 32144686)
6. Langdon WY, Harris AW, Cory S, Adams JM. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell. 1986;47(1):11-18. (Pubitemid 17181528)
7. Iritani BM, Eisenman RN. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci USA. 1999; 96(23):13180-13185.
8. Steiner P, Philipp A, Lukas J, et al. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J. 1995; 14(19):4814-4826.
9. Bouchard C, Thieke K, Maier A, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999;18(19):5321-5333. (Pubitemid 29465582)
10. Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H. Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J. 1999;18(19):5310-5320. (Pubitemid 29465581)
11. Fernandez PC, Frank SR, Wang L, et al. Genomic targets of the human c-Myc protein. Genes Dev. 2003;17(9):1115-1129. (Pubitemid 36534986)
12. Leone G, DeGregori J, Sears R, Jakoi L, Nevins Jr. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature. 1997;387(6631):422-426. (Pubitemid 27227209)
13. Hipfner DR, Cohen SM. Connecting proliferation and apoptosis in development and disease. Nat Rev Mol Cell Biol. 2004;5(10):805-815. (Pubitemid 39336274)
14. Zindy F, Eischen CM, Randle DH, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998;12(15):2424-2433. (Pubitemid 28371361)
15. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999;13(20):2670-2677. (Pubitemid 29508554)
16. Martins CP, Berns A. Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J. 2002;21(14):3739-3748. (Pubitemid 34787047)
17. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res. 2004;10(3): 803-821. (Pubitemid 38198878)
18. Allday MJ. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma? Semin Cancer Biol. 2009;19(6):366-376.
19. Fruehling S, Longnecker R. The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCRmediated signal transduction. Virology. 1997; 235(2):241-251. (Pubitemid 27394337)
20. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity. 1998; 9(3):405-411. (Pubitemid 28462761)
21. Caldwell RG, Brown RC, Longnecker R. Epstein- Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol. 2000;74(3):1101-1113. (Pubitemid 30044059)
22. Mancao C, Hammerschmidt W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood. 2007;110(10):3715-3721. (Pubitemid 350159641)
23. Wasil LR, Tomaszewski MJ, Hoji A, Rowe DT. The effect of Epstein-Barr virus Latent Membrane Protein 2 expression on the kinetics of early B cell infection. PLoS ONE. 2013;8(1):e54010.
24. Bieging KT, Amick AC, Longnecker R. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis. Proc Natl Acad Sci USA. 2009;106(42):17945-17950.
25. Bultema R, Longnecker R, Swanson-Mungerson M. Epstein-Barr virus LMP2A accelerates MYCinduced lymphomagenesis. Oncogene. 2009; 28(11):1471-1476.
26. Refaeli Y, Young RM, Turner BC, Duda J, Field KA, Bishop JM. The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol. 2008; 6(6):e152.
27. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13(20): 2658-2669. (Pubitemid 29508553)
28. Kovalchuk AL, Qi CF, Torrey TA, et al. Burkitt lymphoma in the mouse. J Exp Med. 2000;192(8): 1183-1190.
29. Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev. 2006;20(1):47-64. (Pubitemid 43042667)
30. Bieging KT, Fish K, Bondada S, Longnecker R. A shared gene expression signature in mouse models of EBV-associated and non-EBVassociated Burkitt lymphoma. Blood. 2011; 118(26):6849-6859.
31. Casola S, Otipoby KL, Alimzhanov M, et al. B cell receptor signal strength determines B cell fate. Nat Immunol. 2004;5(3):317-327. (Pubitemid 38332129)
32. Yang W, Shen J, Wu M, et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 2001; 20(14):1688-1702. (Pubitemid 32368016)
33. Chandramohan V, Mineva ND, Burke B, et al. c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor. J Cell Biochem. 2008; 104(6):2091-2106.
34. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269(5224):682-685.
35. Malek NP, Sundberg H, McGrew S, Nakayama K, Kyriakides TR, Roberts JM. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature. 2001;413(6853):323-327. (Pubitemid 32905854)
36. Connor MK, Kotchetkov R, Cariou S, et al. CRM1/ Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell. 2003;14(1): 201-213. (Pubitemid 36106030)
37. Katagiri K, Ueda Y, Tomiyama T, et al. Deficiency of Rap1-binding protein RAPL causes lymphoproliferative disorders through mislocalization of p27kip1. Immunity. 2011;34(1): 24-38.
38. Miller JP, Yeh N, Hofstetter CP, Keskin D, Goldstein AS, Koff A. p27kip1 protein levels reflect a nexus of oncogenic signaling during cell transformation. J Biol Chem. 2012;287(24): 19775-19785.
39. Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol. 2001;21(22): 7653-7662. (Pubitemid 32988776)
40. Garrison SP, Jeffers JR, Yang C, et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol. 2008; 28(17):5391-5402.
41. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA. 2004;101(16): 6164-6169. (Pubitemid 38520545)
42. Keller UB, Old JB, Dorsey FC, et al. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO J. 2007;26(10):2562-2574. (Pubitemid 46788317)
43. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000;183(1):10-17. (Pubitemid 30130220)
44. Cordon-Cardo C, Koff A. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci USA. 1999;96(11): 6382-6387. (Pubitemid 29256674)
45. Di Cristofano A, De Acetis M, Koff A, Cordon- Cardo C, Pandolfi PP. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet. 2001;27(2):222-224. (Pubitemid 32157454)
46. Cipriano SC, Chen L, Burns KH, Koff A, Matzuk MM. Inhibin and p27 interact to regulate gonadal tumorigenesis. Mol Endocrinol. 2001;15(6): 985-996. (Pubitemid 32510644)
47. Philipp-Staheli J, Kim KH, Payne SR, et al. Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice. Cancer Cell. 2002;1(4):355-368. (Pubitemid 41039137)
48. Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclindependent kinase inhibitor function of p27(Kip1). Cell. 1996;85(5):721-732.
49. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haploinsufficient for tumour suppression. Nature. 1998; 396(6707):177-180. (Pubitemid 28523620)
50. Serres MP, Zlotek-Zlotkiewicz E, Concha C, et al. Cytoplasmic p27 is oncogenic and cooperates with Ras both in vivo and in vitro. Oncogene. 2011;30(25):2846-2858.
51. O'Hagan RC, Ohh M, David G, et al. Mycenhanced expression of Cul1 promotes ubiquitindependent proteolysis and cell cycle progression. Genes Dev. 2000;14(17):2185-2191.
52. Old JB, Kratzat S, Hoellein A, et al. Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis. Mol Cancer Res. 2010;8(3):353-362.
53. Bretones G, Acosta JC, Caraballo JM, et al. SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells. J Biol Chem. 2011; 286(11):9815-9825.
54. Kamura T, Hara T, Matsumoto M, et al. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol. 2004;6(12):1229-1235. (Pubitemid 39625122)
55. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999;1(4):193-199. (Pubitemid 129500937)
56. Sutterlüty H, Chatelain E, Marti A, et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol. 1999;1(4): 207-214. (Pubitemid 129500939)
57. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood. 1998;91(4): 1373-1381. (Pubitemid 28086891)
58. Bell AI, Groves K, Kelly GL, et al. Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative realtime PCR assays. J Gen Virol. 2006;87(Pt 10): 2885-2890. (Pubitemid 44463896)
59. Portis T, Longnecker R. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene. 2004;23(53):8619-8628. (Pubitemid 39576469)
60. Dargart JL, Fish K, Gordon LI, Longnecker R, Cen O. Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. Antiviral Res. 2012; 95(1):49-56.
61. Cen O, Longnecker R. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma. Mol Cancer Ther. 2011;10(4): 679-686.